Joshua T Brumm insider trades: Crescent Biopharma (CBIO) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Joshua reports to the SEC
Open-market buys and sales
26 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | CBIO | ↓ Sell10b5-1 | 9,447 | $16.91 | $160K | Direct | Sep 18, 2026 (0d) |
| Jun 22, 2026 | CBIO | ↓ Sell10b5-1 | 42,305 | $17.99 | $761K | Direct | Jun 23, 2026 (1d) |
| Mar 11, 2024 | DYN | ↓ Sell10b5-1 | 429,730 | $25.89 | $11.1M | Direct | Mar 12, 2024 (1d) |
| Mar 7, 2024 | DYN | ↓ Sell10b5-1 | 9,086 | $25.85 | $235K | Direct | Mar 11, 2024 (4d) |
| Mar 1, 2024 | DYN | ↓ Sell | 100,000 | $28.96 | $2.9M | Direct | Mar 1, 2024 (0d) |
| Jan 4, 2024 | DYN | ↓ Sell | 269,719 | $18.66 | $5.0M | Direct | Jan 4, 2024 (0d) |
| Dec 11, 2023 | DYN | ↓ Sell10b5-1 | 7,585 | $10.72 | $81K | Direct | Dec 12, 2023 (1d) |
| Sep 18, 2023 | DYN | ↓ Sell10b5-1 | 12,032 | $9.41 | $113K | Direct | Sep 20, 2023 (2d) |
| Sep 12, 2023 | DYN | ↓ Sell10b5-1 | 7,672 | $10.41 | $80K | Direct | Sep 13, 2023 (1d) |
| Jun 12, 2023 | DYN | ↓ Sell | 325,330 | $12.90 | $4.2M | Direct | Jun 12, 2023 (0d) |
| Mar 14, 2023 | DYN | ↓ Sell10b5-1 | 7,318 | $13.33 | $98K | Direct | Mar 15, 2023 (1d) |
| Dec 12, 2022 | DYN | ↓ Sell10b5-1 | 3,322 | $10.87 | $36K | Direct | Dec 13, 2022 (1d) |
| Oct 10, 2022 | DYN | ↓ Sell | 210,000 | $12.52 | $2.6M | Direct | Oct 11, 2022 (1d) |
| Mar 11, 2022 | DYN | ↓ Sell10b5-1 | 3,384 | $8.73 | $30K | Direct | Mar 14, 2022 (3d) |
| Sep 21, 2021 | DYN | ↓ Sell10b5-1 | 8,009 | $15.90 | $127K | Direct | Sep 22, 2021 (1d) |
| Oct 19, 2017 | VSAR | ↓ Sell | 1,326 | $2.55 | $3K | Direct | Oct 23, 2017 (4d) |
| Jun 13, 2017 | VSAR | ↓ Sell | 1,421 | $16.05 | $23K | Direct | Jun 14, 2017 (1d) |
| May 16, 2017 | VSAR | ↓ Sell | 1,263 | $17.40 | $22K | Direct | May 17, 2017 (1d) |
| Feb 24, 2017 | VSAR | ↓ Sell | 30,000 | $20.94 | $628K | Direct | Feb 28, 2017 (4d) |
| Jan 30, 2017 | VSAR | ↓ Sell | 2,945 | $13.85 | $41K | Direct | Jan 31, 2017 (1d) |
| Dec 27, 2016 | VSAR | ↓ Sell | 990 | $15.85 | $16K | Direct | Dec 29, 2016 (2d) |
| Dec 7, 2016 | VSAR | ↓ Sell | 3,021 | $13.25 | $40K | Direct | Dec 8, 2016 (1d) |
| Jun 15, 2016 | VSAR | ↓ Sell | 1,448 | $10.63 | $15K | Direct | Jun 17, 2016 (2d) |
| May 20, 2016 | VSAR | ↓ Sell | 1,265 | $7.87 | $10K | Direct | May 20, 2016 (0d) |
| Dec 30, 2015 | VSAR | ↓ Sell | 990 | $12.44 | $12K | Direct | Jan 4, 2016 (5d) |
| Nov 12, 2015 | VSAR | ↑ Buy | 2,500 | $9.99 | $25K | Direct | Nov 13, 2015 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CBIO insiders
Open-market trades in the last 12 months
About Joshua T Brumm's insider trades
Joshua T Brumm is Chief Executive Officer at Crescent Biopharma (CBIO). Since Nov 12, 2015, Joshua has reported 1 open-market purchase worth $25K and 25 sales worth $28.4M on SEC Form 4. In the last 12 months: 2 sales ($921K).
11 sales (45% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (18 filings), option exercises (6 filings), gifts (4 filings), shares returned to the company (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CBIO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.